Fighting back: Peptidomimetics as a new weapon in the battle against antibiotic resistance

Science Translational Medicine

Volumn 2, Issue 21, 2010, Pages

  Bragonzi, Alessandra ^a  

^a Obstetrics and Gynaecology Department   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; BACTERIUM LIPOPOLYSACCHARIDE; DAPTOMYCIN; GENTAMICIN; LINEZOLID; NALIDIXIC ACID; OUTER MEMBRANE PROTEIN; POL 7001; POL 7080; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEGRIN; PROTEGRIN I; RETAPAMULIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL GENOME; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; BIOFILM; COMMUNICABLE DISEASE; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG BINDING; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUSTRY; DRUG ISOLATION; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG RESEARCH; DRUG SCREENING; ENTEROCOCCAL INFECTION; ERADICATION THERAPY; GENOME ANALYSIS; GRAM NEGATIVE INFECTION; GRAM NEGATIVE SEPSIS; GRAM POSITIVE INFECTION; HEALTH CARE FINANCING; HOSPITAL INFECTION; HOST PATHOGEN INTERACTION; HUMAN; INFECTION CONTROL; INNATE IMMUNITY; INVESTMENT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RISK MANAGEMENT; SCIENTIFIC LITERATURE; SHORT SURVEY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIA; BIOMIMETICS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; SEPSIS;

EID: 77953017278     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000889     Document Type: Short Survey

References (31)

1. Infectious Diseases Society of America, Bad bugs, no drugs. As antibiotic discovery stagnates . . . A public health crisis brews (2004) (http://www.idsociety.org/badbugsnodrugs.html).
2. B. Spellberg, J. H. Powers, E. P. Brass, L. G. Miller, J. E. Edwards Jr., Trends in antimicrobial drug development: Implications for the future. Clin. Infect. Dis. 38, 1279-1286 (2004).
3. J. A. DiMasi, R. W. Hansen, H. G. Grabowski, The price of innovation: New estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
4. D. J. Payne, M. N. Gwynn, D. J. Holmes, D. L. Pompliano, Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29-40 (2007).
5. P. Fernandes, Antibacterial discovery and development- the failure of success? Nat. Biotechnol. 24, 1497-1503 (2006).
6. N. Srinivas, P. Jetter, B. J. Ueberbacher, M. Werneburg, K. Zerbe, J. Steinmann, B. Van der Meijden, F. Bernardini, A. Lederer, R. L. A. Dias, P. E. Misson, H. Henze, J. Zumbrunn, F. O. Gombert, D. Obrecht, P. Hunziker, S. Schauer, U. Ziegler, A. Käch, L. Eberl, K. Riedel, S. J. DeMarco, J. A. Robinson, Peptidomimetic antibiotics target outer membrane biogenesis in Pseudomonas aeruginosa. Science 327, 1010-1013 (2010).
7. M. Leeb, Antibiotics: A shot in the arm. Nature 431, 892-893 (2004).
8. A. Coates, Y. Hu, R. Bax, C. Page, The future challenges facing the development of new antimicrobial drugs. Nat. Rev. Drug Discov. 1, 895-910 (2002).
9. H. W. Boucher, G. H. Talbot, J. S. Bradley, J. E. Edwards, D. Gilbert, L. B. Rice, M. Scheld, B. Spellberg, J. Bartlett, Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1-12 (2009).
10. S. J. Projan, P. J. Youngman, Antimicrobials: New solutions badly needed. Curr. Opin. Microbiol. 5, 463-465 (2002).
11. R. E. Hancock, Cationic peptides: Effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis. 1, 156-164 (2001).
12. J. P. Powers, R. E. Hancock, The relationship between peptide structure and antibacterial activity. Peptides 24, 1681-1691 (2003).
13. N. Sitaram, R. Nagaraj, Host-defense antimicrobial peptides: Importance of structure for activity. Curr. Pharm. Des. 8, 727-742 (2002). (Pubitemid 34498562)
14. W. van't Hof, E. C. Veerman, E. J. Helmerhorst, A. V. Amerongen, Antimicrobial peptides: Properties and applicability. Biol. Chem. 382, 597-619 (2001).
15. J. A. Robinson, S. C. Shankaramma, P. Jetter, U. Kienzl, R. A. Schwendener, J. W. Vrijbloed, D. Obrecht, Properties and structure-activity studies of cyclic beta-hairpin peptidomimetics based on the cationic antimicrobial peptide protegrin I. Bioorg. Med. Chem. 13, 2055-2064 (2005).
16. S. C. Shankaramma, Z. Athanassiou, O. Zerbe, K. Moehle, C. Mouton, F. Bernardini, J. W. Vrijbloed, D. Obrecht, J. A. Robinson, Macrocyclic hairpin mimetics of the cationic antimicrobial peptide protegrin I: A new family of broadspectrum antibiotics. ChemBioChem 3, 1126-1133 (2002).
17. S. C. Shankaramma, K. Moehle, S. James, J. W. Vrijbloed, D. Obrecht, J. A. Robinson, A family of macrocyclic antibiotics with a mixed peptide-peptoid beta-hairpin backbone conformation. Chem. Commun. (Camb.) 15, 1842-1843 (2003).
18. C. K. Stover, X. Q. Pham, A. L. Erwin, S. D. Mizoguchi, P. Warrener, M. J. Hickey, F. S. Brinkman, W. O. Hufnagle, D. J. Kowalik, M. Lagrou, R. L. Garber, L. Goltry, E. Tolentino, S. Westbrock-Wadman, Y. Yuan, L. L. Brody, S. N. Coulter, K. R. Folger, A. Kas, K. Larbig, R. Lim, K. Smith, D. Spencer, G. K. Wong, Z. Wu, I. T. Paulsen, J. Reizer, M. H. Saier, R. E. Hancock, S. Lory, M. V. Olson, Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406, 959-964 (2000).
19. M. G. Page, J. Heim, Prospects for the next anti-Pseudomonas drug. Curr. Opin. Pharmacol. 9, 558-565 (2009).
20. M. P. Bos, V. Robert, J. Tommassen, Biogenesis of the gram-negative bacterial outer membrane. Annu. Rev. Microbiol. 61, 191-214 (2007).
21. M. Braun, T. J. Silhavy, Imp/OstA is required for cell envelope biogenesis in Escherichia coli. Mol. Microbiol. 45, 1289-1302 (2002).
22. T. Wu, J. Malinverni, N. Ruiz, S. Kim, T. J. Silhavy, D. Kahne, Identification of a multicomponent complex required for outer membrane biogenesis in Escherichia coli. Cell 121, 235-245 (2005).
23. T. Wu, A. C. McCandlish, L. S. Gronenberg, S. S. Chng, T. J. Silhavy, D. Kahne, Identification of a protein complex that assembles lipopolysaccharide in the outer membrane of Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 103, 11754-11759 (2006). (Pubitemid 44182523)
24. P. Sperandeo, F. K. Lau, A. Carpentieri, C. De Castro, A. Molinaro, G. Dehò, T. J. Silhavy, A. Polissi, Functional analysis of the protein machinery required for transport of lipopolysaccharide to the outer membrane of Escherichia coli. J. Bacteriol. 190, 4460-4469 (2008).
25. D. Nguyen, P. K. Singh, Evolving stealth: Genetic adaptation of Pseudomonas aeruginosa during cystic fibrosis infections. Proc. Natl. Acad. Sci. U.S.A. 103, 8305-8306 (2006).
26. E. E. Smith, D. G. Buckley, Z. Wu, C. Saenphimmachak, L. R. Hoffman, D. A. D'Argenio, S. I. Miller, B. W. Ramsey, D. P. Speert, S. M. Moskowitz, J. L. Burns, R. Kaul, M. V. Olson, Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl. Acad. Sci. U.S.A. 103, 8487-8492 (2006).
27. B. Tümmler, Clonal variations in Pseudomonas aeruginosa, in Pseudomonas, J.-L. Ramos and R.C. Levesque, Eds. (Springer, Heidelberg, Germany, 2006), pp. 35-68.
28. C. Cigana, L. Curcurù, M. R. Leone, T. Ieranò, N. I. Lorè, I. Bianconi, A. Silipo, F. Cozzolino, R. Lanzetta, A. Molinaro, M. L. Bernardini, A. Bragonzi, E. Moreno, Pseudomonas aeruginosa exploits lipid A and muropeptides modifi cation as a strategy to lower innate immunity during cystic fibrosis lung infection. PLoS ONE 4, e8439 (2009).
29. G. P. Bodey, R. Bolivar, V. Fainstein, L. Jadeja, Infections caused by Pseudomonas aeruginosa. Rev. Infect. Dis. 5, 279-313 (1983).
30. F. Ratjen, G. Döring, Cystic fibrosis. Lancet 361, 681-689 (2003).
31. A. Bragonzi, M. Paroni, A. Nonis, N. Cramer, S. Montanari, J. Rejman, C. Di Serio, G. Döring, B. Tümmler, Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. Am. J. Respir. Crit. Care Med. 180, 138-145 (2009).